Experimental antibody relieves pruritus in atopic dermatitis
The results come from a four-month phase 3 clinical trial
Subcutaneous abdominal injections of the experimental monoclonal antibody nemolizumab produced significant improvement in patients with atopic dermatitis and moderate-to-severe pruritus, a study shows.